L Lisata Therapeutics
L
Gesloten
3.16 2.6
Overzicht
Wijziging aandelenprijs
24u
Min
3.12
Max
3.17
Inkomsten | 1.3M -3M |
|---|---|
Verkoop | 100K 100K |
Winstmarge | -2,954 |
Werknemers | 21 |
Volgende Winsten | 6 aug 2026 |
|---|
Marktkapitalisatie | -16M 24M |
|---|---|
Vorige openingsprijs | 0.56 |
Vorige sluitingsprijs | 3.16 |
Lisata Therapeutics Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Gerelateerd nieuws
Peer Vergelijking
Prijswijziging
Lisata Therapeutics Prognose
Financieel
Verkoop- en administratiekosten
Winst voor belastingen
Verkoop
Operationele winst
$
Over Lisata Therapeutics
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.